Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.1016552
Keywords
liver fibrosis; hepatic stellate cell; cyclin-dependent kinase 9; apoptosis; activation; proliferation
Categories
Funding
- National Natural Foundation of China
- Shanghai Science and Technology Committee [82130120, 81530101, 82205009]
- CAST [20S21902600]
- Shanghai Municipal Education Commission and Shanghai Education Development Foundation [2020QNRC001]
- Special Project for Clinical Research of Shanghai Municipal Health Commission [20CG50]
- Shanghai University of Traditional Chinese Medicine [20214Y0178]
- Science Foundation of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine [2021LK092]
- China Postdoctoral Science Foundation [2021yygq01]
- Shanghai Post-doctoral Excellence Program [2021M702218]
- [2020372]
Ask authors/readers for more resources
SNS-032 alleviates liver fibrosis by inhibiting the activation and inducing the apoptosis of active HSCs. CDK9 could be a potential target for the treatment of liver fibrosis.
Liver fibrosis is a common pathological process of all chronic liver diseases. Hepatic stellate cells (HSCs) play a central role in the development of liver fibrosis. Cyclin-dependent kinase 9 (CDK9) is a cell cycle kinase that regulates mRNA transcription and elongation. A CDK9 inhibitor SNS-032 has been reported to have good effects in anti-tumor. However, the role of SNS-032 in the development of liver fibrosis is unclear. In this study, SNS-032 was found to alleviate hepatic fibrosis by inhibiting the activation and inducing the apoptosis of active HSCs in carbon tetrachloride-induced model mice. In vitro, SNS-032 inhibited the activation and proliferation of active HSCs and induced the apoptosis of active HSCs by downregulating the expression of CDK9 and its downstream signal transductors, such phosphorylated RNA polymerase II and Bcl-2. CDK9 short hairpin RNA was transfected into active HSCs to further elucidate the mechanism of the above effects. Similar results were observed in active HSCs after CDK9 knockdown. In active HSCs with CDK9 knockdown, the expression levels of CDK9, phosphorylated RNA polymerase II, XIAP, Bcl-2, Mcl-1, and ?-SMA significantly decreased, whereas those of cleaved-PARP1 and Bax decreased prominently. These results indicated that SNS-032 is a potential drug and CDK9 might be a new prospective target for the treatment of liver fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available